[12] Patent
[11] Patent No.:GC0007594  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126079
Date of the Decision to Grant the Patent:16/Apr/2018

[21] Application No.:GC 2014-26913

[22] Filing Date:27/3/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
29/3/2013
16/12/2013
61/806,806
61/916,715

[72] Inventors:1- BROWN, Jason W.،2- DAVIS, Melinda،3- IVETAC, Anthony،4- JONES, Benjamin،5- KIRYANOV, Andre A.،6- KEUHLER, Jon،7- LANIER, Marion،8- MIURA, Joanne،9- MURPHY, Sean،10- WANG, Xiaolum

[73] Owner: TAKEDA PHARMACEUTICAL COMPANY LIMITED , 1-1, Doshomachi 4-chome, Chuo – ku, Osaka-shi 541-0045, Osaka , Japan

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: A61K 31/443, 31/4433, 31/4436, 31/4439, 31/4545, 31/496; C07D 401/04, 401/14, 405/14, 413/14, 417/14, 471/08, 487/06, 487/10, 491/10 (2006.01)

[56] Cited Documents:

-US 2010093803 A1 (THEDE KAI [DE] ET AL) 15 April 2010
-US 2010305085 A1 (THEDE KAI [DE] ET AL) 2 December 2010
-US 2011294788 A1 (ALTENBURGER JEAN-MICHEL [FR] ET AL) 1 December 2011
 
Examiner: PH. Mohammad S. AlMousa

[54] 6-5-HYDROXY-1H-PYRAZOL-1-YLNICOTINAMIDE INHIBITORS OF PHD
[57] Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
No. of claims: 17


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.